Revolution Medicines (NASDAQ:RVMD) Earns “Outperform” Rating from Wedbush

Revolution Medicines (NASDAQ:RVMD)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a research report issued to clients and investors on Tuesday,Benzinga reports.

A number of other research firms also recently weighed in on RVMD. Truist Financial raised Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, March 25th. Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Evercore reissued an “outperform” rating on shares of Revolution Medicines in a research note on Tuesday. UBS Group assumed coverage on Revolution Medicines in a research note on Friday, February 27th. They issued a “buy” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research note on Thursday, January 22nd. Four analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $78.94.

Revolution Medicines Stock Up 3.8%

RVMD opened at $152.54 on Tuesday. Revolution Medicines has a fifty-two week low of $34.00 and a fifty-two week high of $155.01. The business has a 50-day moving average of $101.04 and a 200-day moving average of $84.75. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. The company has a market capitalization of $30.23 billion, a PE ratio of -25.81 and a beta of 1.01.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same period in the prior year, the firm earned ($1.12) earnings per share. Equities research analysts forecast that Revolution Medicines will post -3.49 EPS for the current fiscal year.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, insider Mark A. Goldsmith sold 12,871 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $1,280,407.08. Following the sale, the insider owned 276,698 shares of the company’s stock, valued at $27,525,917.04. This trade represents a 4.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Margaret A. Horn sold 4,583 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $455,916.84. Following the completion of the sale, the chief operating officer directly owned 157,570 shares in the company, valued at $15,675,063.60. This trade represents a 2.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 64,592 shares of company stock worth $6,488,732. Insiders own 8.20% of the company’s stock.

Institutional Trading of Revolution Medicines

Institutional investors have recently modified their holdings of the company. New York State Common Retirement Fund grew its holdings in shares of Revolution Medicines by 39.3% during the 3rd quarter. New York State Common Retirement Fund now owns 119,807 shares of the company’s stock worth $5,595,000 after purchasing an additional 33,821 shares in the last quarter. Raiffeisen Bank International AG acquired a new stake in shares of Revolution Medicines during the 3rd quarter worth approximately $921,000. NEOS Investment Management LLC grew its holdings in shares of Revolution Medicines by 34.7% during the 3rd quarter. NEOS Investment Management LLC now owns 126,921 shares of the company’s stock worth $5,927,000 after purchasing an additional 32,694 shares in the last quarter. HighVista Strategies LLC grew its holdings in shares of Revolution Medicines by 157.8% during the 3rd quarter. HighVista Strategies LLC now owns 175,448 shares of the company’s stock worth $8,193,000 after purchasing an additional 107,400 shares in the last quarter. Finally, Tema Etfs LLC grew its holdings in shares of Revolution Medicines by 34.7% during the 3rd quarter. Tema Etfs LLC now owns 126,921 shares of the company’s stock worth $5,927,000 after purchasing an additional 32,694 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Phase III pancreatic-cancer win: daraxonrasib’s positive Phase III data showing survival benefit in metastatic PDAC drove the stock rally and materially improves the company’s regulatory and commercial outlook. RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
• Positive Sentiment: Analyst bullishness: Several outlets and analysts are calling a buy/strong-buy after the clinical readout, reinforcing demand and supporting higher price targets. This adds sell-side support for near-term momentum. Revolution Medicines: ‘Strong Buy’ On Daraxonrasib Win And Expansions Underway
• Positive Sentiment: Wedbush reaffirmation: Wedbush reiterated an “Outperform” rating, which can reinforce institutional confidence after the data release. Revolution Medicines’ (RVMD) “Outperform” Rating Reaffirmed at Wedbush
• Neutral Sentiment: Major upsized financing priced: Revolution priced concurrent offerings of common stock and 0.50% convertible senior notes (common stock offering increased to ~10.56M shares at $142 each; $500M notes), which significantly bolsters cash for R&D and potential commercialization but also increases share count potential. Settlement dates are mid‑April. Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
• Neutral Sentiment: Options and volume signal momentum: Unusual call buying and very high share volume indicate speculative and directional interest following the data — this can amplify intraday moves but increases volatility risk. (Internal/market data)
• Negative Sentiment: Dilution and conversion terms to watch: The convertible notes carry a conversion price materially above the offering price (initial conversion price ~ $198.80 per share) but the equity raise itself and heavy insider selling noted in recent filings represent dilution risk and potential pressure if insiders continue to sell into strength. Revolution Medicines Announces Pricing of $1.5 Billion Common Stock and Convertible Note Offerings

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.